Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

VoxChameleon May. 15 at 2:46 AM

$ABCL $4.34 overnight trading. Lmfao.

0 · Reply

Kaykay610 May. 15 at 1:56 AM

$ABCL biotech is not for the weak, dont panick my longs we have been here before

1 · Reply

VoxChameleon May. 14 at 11:21 PM

$ABCL Canadian gov gave this turd 700 million just a couple years back to help build facilities but is still down close to 90% since ipo And treated like a shit penny stock. Canada facking sucks especially the “men” who run companies.

1 · Reply

VoxChameleon May. 14 at 11:17 PM

$ABCL still shorting this Canadian turd in ah lol. Going for -30% in 3 days. But off high more like 40%. So pathetic.

0 · Reply

Ed_Ng May. 14 at 10:22 PM

$ABCL I tell you again: this is the next Theranos, but penny level

0 · Reply

Ed_Ng May. 14 at 10:21 PM

$ABCL liar

1 · Reply

Samb2344 May. 14 at 10:13 PM

$ABCL I added just for us to dip off.. love it

0 · Reply

Ed_Ng May. 14 at 9:43 PM

$ABCL so happy now. Thanks everyone!

1 · Reply

tradersunion353 May. 14 at 9:43 PM

$ABCL who are these clowns still pumping this overhyped underperforming junk

0 · Reply

snowPOW May. 14 at 8:55 PM

$ABCL interesting noise today.

0 · Reply

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 2 days ago

AbCellera price target raised to $8 from $7 at Stifel

2026-05-11T21:58:40.000Z - 3 days ago

AbCellera Biologics options imply 9.7% move in share price post-earnings

May 11, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 days ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 7 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 9 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 21, 2026, 1:30 PM EDT - 23 days ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 24 days ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 5 weeks ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 6 weeks ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 2 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

2026-02-24T21:15:21.000Z - 2 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 4 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T14:36:23.000Z - 4 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 4 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 5 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

2025-11-07T11:16:20.000Z - 6 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

Nov 6, 2025, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

2025-09-10T13:20:54.000Z - 8 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 8 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

2025-08-08T13:26:29.000Z - 9 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

2025-06-11T13:45:23.000Z - 1 year ago

Unusually active option classes on open June 11th

AFRM BILI FXE LAES PCG QUBT RGTI

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

2025-05-30T17:05:30.000Z - 1 year ago

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

VoxChameleon May. 15 at 2:46 AM

$ABCL $4.34 overnight trading. Lmfao.

0 · Reply

Kaykay610 May. 15 at 1:56 AM

$ABCL biotech is not for the weak, dont panick my longs we have been here before

1 · Reply

VoxChameleon May. 14 at 11:21 PM

1 · Reply

VoxChameleon May. 14 at 11:17 PM

$ABCL still shorting this Canadian turd in ah lol. Going for -30% in 3 days. But off high more like 40%. So pathetic.

0 · Reply

Ed_Ng May. 14 at 10:22 PM

$ABCL I tell you again: this is the next Theranos, but penny level

0 · Reply

Ed_Ng May. 14 at 10:21 PM

$ABCL liar

1 · Reply

Samb2344 May. 14 at 10:13 PM

$ABCL I added just for us to dip off.. love it

0 · Reply

Ed_Ng May. 14 at 9:43 PM

$ABCL so happy now. Thanks everyone!

1 · Reply

tradersunion353 May. 14 at 9:43 PM

$ABCL who are these clowns still pumping this overhyped underperforming junk

0 · Reply

snowPOW May. 14 at 8:55 PM

$ABCL interesting noise today.

0 · Reply

VoxChameleon May. 14 at 8:55 PM

$ABCL you are all smart enough that this will be over $5 by next week. It’s fun to talk smack but let’s be real. Average is $4.53. 11k shares. I’ll make $5K and call It a day. Go Canada.

1 · Reply

nUme22 May. 14 at 8:39 PM

$ABCL always the truth.. Canadian scams. almost as bad as Israeli scams

1 · Reply

PorkchopSquats May. 14 at 8:36 PM

$ABCL @DeMampCamp Still bullish long term, but you’re still an idiot short term.

1 · Reply

tradersunion353 May. 14 at 8:21 PM

$ABCL clowns how is that pumpiny adding and loading work i told you not to fall for that demamp clown zero hopes that this willl rise on phase 2 data

2 · Reply

Plan2TradeTrade2Plan May. 14 at 8:02 PM

$ABCL the news is out. Nowhere to go but down I guess. Can’t find support.

1 · Reply

VoxChameleon May. 14 at 7:59 PM

$ABCL Canada. Lmfao.

0 · Reply

sogenerous May. 14 at 7:58 PM

$ABCL I mean what did you expect ?

2 · Reply

VoxChameleon May. 14 at 7:54 PM

$ABCL lmfao!!!! What a pos.

0 · Reply

VoxChameleon May. 14 at 7:45 PM

$ABCL close a 1.5 billion dollar Canadian company low of day -7% on no news. 20-% in 3 days. So fitting for that weak ass country.

0 · Reply

VoxChameleon May. 14 at 7:32 PM

$ABCL freaken Canadians man. Oh golly gee they shorted us 20% + in 3 days but we say nothing. Weak ass country man.

1 · Reply

VoxChameleon May. 14 at 7:26 PM

$ABCL a stock like this 1.5 billion cap shouldn’t go down 7% on no news. Brutal.

1 · Reply

VoxChameleon May. 14 at 7:22 PM

$ABCL bought too many shares at average $4.58. Oh well. It will definitely surpass that and be $5+ soon once these savages relax.

1 · Reply

Market Cap	1.46B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	7,367,800
Avg Vol	5,225,826
Day's Range	N/A - N/A
Shares Out	305.38M
Stochastic %K	3%
Beta	1.02
Analysts	Strong Sell
Price Target	$10.14